China News Service, January 18th (Zuo Yuqing, Zhongxin Finance and Economics) On the 18th, Zhongxin Finance learned from the press conference on the adjustment of the 2022 National Medical Insurance Drug Catalog that the 2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog The adjustment work has now been successfully completed.
In this adjustment, a total of 111 drugs were added to the list, and 3 drugs were removed from the list.
Judging from the negotiation and bidding situation, 147 drugs outside the list participated in the negotiation and bidding (including the renewal negotiation of drugs in the original list), and
121 drugs were successfully negotiated or bid, with an overall success rate of 82.3%, a record high
.
Negotiations and bidding for newly admitted drugs have seen an average price drop of 60.1%
.
After this round of adjustments, the total number of drugs in the national medical insurance drug catalog has reached 2,967, including 1,586 Western medicines and 1,381 Chinese patent medicines; Chinese herbal medicines have not been adjusted, and the number is still 892.
From the perspective of patients' burden, through negotiation of price reduction and medical insurance reimbursement, this adjustment is expected to reduce the burden of patients by more than 90 billion yuan in the next two years.
(Finish)